BMJ Open. 2026 Aug 21;16(8):e120631. doi: 10.1136/bmjopen-2026-120631.
ABSTRACT
INTRODUCTION: Fracture misdiagnosis is a common diagnostic error in emergency departments (EDs) and minor injury units (MIUs), leading to poor patient outcomes, unnecessary treatments and significant healthcare costs. Artificial intelligence (AI)-assisted fracture detection tools are now available for use in radiology workflows; however, the impact of these technologies on patient outcomes, experiences and overall care pathways in the real-world clinical setting is limited.
METHODS AND ANALYSIS: We will conduct a prospective cluster randomised cross-over trial over a 6-month period, assessing the impact of an AI-assisted fracture detection tool in EDs and MIUs across 4 healthcare Trusts in the UK. Patients aged over 2 years old undergoing a plain film radiography for a suspected fracture as part of routine clinical care will be eligible for study enrolment. The trial will deploy Radiobotics’ RBfracture, a CE-approved AI-assisted medical device software for fracture detection at each site for 6 months. Randomisation will be at a cluster-level; a site will be randomised to begin with ‘AI on’ or ‘AI off’ for a month, followed by alternating active status each month for the remaining 5 months. The primary outcome will evaluate the incidence of ‘inappropriate healthcare contacts’ among patients receiving imaging for suspected fractures. This composite metric encompasses inappropriate referrals to fracture clinics, repeated hospital attendances and subsequent follow-up communications regarding missed fractures. The rates of these measures will be compared in the ‘AI on’ versus ‘AI off’ stages. Secondary outcomes will include patient-reported outcomes, clinician surveys, a predefined health economic evaluation assessing cost-effectiveness and budget impact and the diagnostic performance of the algorithm.
ETHICS AND DISSEMINATION: The study has received ethical approval from the South Central-Oxford Research Ethics Committee (Reference: 25/SC/0252, approval date: 23 October 2025), and subsequently from the Health Research Authority (IRAS 3 57 391-A). The results of this study will be presented at relevant scientific conferences and peer-reviewed publications will be disseminated on wider public forums such as traditional and social media.
REGISTRATION DETAILS: This is an ongoing, actively recruiting trial (ISRCTN23087950). Recruitment began in January 2026 and will run for 6 months at each site, with per-patient follow-up of 30 days and subsequent data analysis. This manuscript describes protocol version 1.1. The full protocol and statistical analysis plan are available from the corresponding author on request and will be deposited on the study’s public repository (https://github.com/Jason-L-Oke/SAMURAI) prior to publication of results.
TRIAL REGISTRATION NUMBER: ISRCTN23087950.
PMID:42629153 | DOI:10.1136/bmjopen-2026-120631
